ES2467968T3 - Regímenes de dosificación de un agente antitumoral que comprende un derivado de desoxicitidina - Google Patents

Regímenes de dosificación de un agente antitumoral que comprende un derivado de desoxicitidina Download PDF

Info

Publication number
ES2467968T3
ES2467968T3 ES09738900.1T ES09738900T ES2467968T3 ES 2467968 T3 ES2467968 T3 ES 2467968T3 ES 09738900 T ES09738900 T ES 09738900T ES 2467968 T3 ES2467968 T3 ES 2467968T3
Authority
ES
Spain
Prior art keywords
cyano
deoxy
pyrimidinone
arabinofuranosyl
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09738900.1T
Other languages
English (en)
Spanish (es)
Inventor
Hiroyuki Okabe
Kazuhito Arakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Delta Fly Pharma Inc
Original Assignee
Taiho Pharmaceutical Co Ltd
Delta Fly Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd, Delta Fly Pharma Inc filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2467968T3 publication Critical patent/ES2467968T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES09738900.1T 2008-04-29 2009-04-28 Regímenes de dosificación de un agente antitumoral que comprende un derivado de desoxicitidina Active ES2467968T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/111,369 US7863255B2 (en) 2008-04-29 2008-04-29 Methods of administering antitumor agent comprising deoxycytidine derivative
US111369 2008-04-29
PCT/JP2009/058725 WO2009133963A1 (en) 2008-04-29 2009-04-28 Methods of administering antitumor agent comprising deoxycytidine derivative

Publications (1)

Publication Number Publication Date
ES2467968T3 true ES2467968T3 (es) 2014-06-13

Family

ID=41050984

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09738900.1T Active ES2467968T3 (es) 2008-04-29 2009-04-28 Regímenes de dosificación de un agente antitumoral que comprende un derivado de desoxicitidina

Country Status (8)

Country Link
US (1) US7863255B2 (https=)
EP (1) EP2268287B1 (https=)
JP (1) JP5570429B2 (https=)
AU (1) AU2009240908B2 (https=)
DK (1) DK2268287T3 (https=)
ES (1) ES2467968T3 (https=)
PL (1) PL2268287T3 (https=)
WO (1) WO2009133963A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤
CN113727719A (zh) 2020-07-17 2021-11-30 德尔塔菲制药股份有限公司 血癌的新型治疗方法及新型治疗剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
GB0328180D0 (en) * 2003-12-04 2004-01-07 Cyclacel Ltd Combination
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination

Also Published As

Publication number Publication date
JP5570429B2 (ja) 2014-08-13
EP2268287A1 (en) 2011-01-05
US20090270340A1 (en) 2009-10-29
AU2009240908B2 (en) 2013-10-03
PL2268287T3 (pl) 2014-10-31
US7863255B2 (en) 2011-01-04
JP2011518761A (ja) 2011-06-30
DK2268287T3 (da) 2014-06-02
EP2268287B1 (en) 2014-05-21
WO2009133963A1 (en) 2009-11-05
AU2009240908A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
ES2424476T3 (es) Nanopartículas cargadas con fármaco antitumoral quimioterápico
ES2717898T3 (es) Efecto potenciador para agentes antitumorales
ES2282400T3 (es) Composiciones antitumorales que contienen derivados de taxano.
ES2255287T3 (es) Composiciones para el tratamiento de la leucemia linfocitica cronica.
ES2272279T3 (es) Uso del compuesto et-743 para el tratamiento del cancer.
JP2012062329A (ja) 併用化学療法
ES2848706T3 (es) Terapia de combinación contra el cáncer usando un compuesto azabicíclico
ES2287495T3 (es) Forma polimorfa cristalina de clorhidrato de irinotecan.
KR100717916B1 (ko) 캄프토테신 및 피리미딘 유도체를 포함하는 암 치료용 조성물
ES2960601T3 (es) Composiciones y métodos para el tratamiento del cáncer
SK10602003A3 (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
KR20100137570A (ko) 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ
ES3037447T3 (en) The compound of formula (i) and ponatinib for use in the treatment of chronic myeloid leukemia with bcr-abl mutations
ES2467968T3 (es) Regímenes de dosificación de un agente antitumoral que comprende un derivado de desoxicitidina
ES2267841T3 (es) Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer.
ES3028873T3 (en) Small molecules for the treatment of primary cancer and cancer metastasis
WO2015191563A1 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin c
ES3038469T3 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
ES2317913T3 (es) Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito.
ES2289483T3 (es) Procedimiento para el tratamiento del cancer hepatico mediante la administracion intrahepatica de nemorubicina.
JP5066737B2 (ja) シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
ES2922752T3 (es) Composición combinada para prevenir o tratar el cáncer que comprende un derivado de benzofenona-tiazol como VDA y un inhibidor de topoisomerasa
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
EP2711009A1 (en) Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
US20060258736A1 (en) Dosing regimen